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Abstract
Background: After spinal cord injury (SCI), the formation of glial scar contributes to the failure of injured adult axons to
regenerate past the lesion. Increasing evidence indicates that olfactory ensheathing cells (OECs) implanted into spinal cord
are found to migrate into the lesion site and induce axons regeneration beyond glial scar and resumption of functions.
However, little is known about the mechanisms of OECs migrating from injection site to glial scar/lesion site.
Methods and Findings: In the present study, we identified a link between OECs migration and reactive astrocytes in glial
scar that was mediated by the tumor necrosis factor-a (TNF-a). Initially, the Boyden chamber migration assay showed that
both glial scar tissue and reactive astrocyte-conditioned medium promoted OECs migration in vitro. Reactive astrocyte-
derived TNF-a and its type 1 receptor TNFR1 expressed on OECs were identified to be responsible for the promoting effect
on OECs migration. TNF-a-induced OECs migration was demonstrated depending on activation of the extracellular signal-
regulated kinase (ERK) signaling cascades. Furthermore, TNF-a secreted by reactive astrocytes in glial scar was also showed
to attract OECs migration in a spinal cord hemisection injury model of rat.
Conclusions: These findings showed that TNF-a was released by reactive astrocytes in glial scar and attracted OECs
migration by interacting with TNFR1 expressed on OECs via regulation of ERK signaling. This migration-attracting effect of
reactive astrocytes on OECs may suggest a mechanism for guiding OECs migration into glial scar, which is crucial for OECs-
mediated axons regrowth beyond the spinal cord lesion site.
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Introduction
Damage to adult mammalian central nervous system (CNS)
leads to persistent functional deficits for the lack of axonal
regeneration and reconnection with correct synaptic targets. The
failure of spontaneous anatomical and functional repair is due not
merely to the intrinsic incapacity of the neuron to regenerate but
rather to the presence of a hostile environment in the lesion site. As
the major cell type in CNS, astrocytes provide a variety of critical
supportive functions that maintain neuronal homeostasis. When
the CNS is damaged, astrocytes undergo an injury response and
become reactive, characterized by hyperplasia, hypertrophy and
an massive up-regulation of intermediate filament (IF) proteins,
and leads eventually to the formation of a dense glial scar network
at the lesion site [1]. The glial scar which composed primarily of
reactive astrocytes has long been implicated as a major
impediment to axon regeneration and functional outcome after
SCI and other forms of CNS injury [2,3]. It constitutes a
mechanical obstacle and a biochemical barrier to preventing
successful regeneration, as several classes of growth inhibitory
molecules are upregulated and have been shown to contribute to
the failure of axon regeneration [2,4,5,6]. On the other hand,
increasing evidence indicates that glial scar might also possess
several important beneficial functions such as stabilizing fragile
CNS tissue after injury [7,8,9]. After injury, reactive astrocytes
form a dense scar tissue that has been suggested to seclude
inflammatory cells, demarcate the lesion area, and separate the
injured tissue from its surroundings [9]. Astrocytes have an
important scavenging activity, which is crucial for regulating
excessive levels of glutamate, K
+ and other ions [10]. Moreover,
the glial scar is reported to fill the gaps in the lesion area, creating
a scaffold for the vascularization network [11].
Olfactory ensheathing cells (OECs) are the glial cells that derive
from the olfactory placode and envelop olfactory axons in the
course of migration from the olfactory epithelium to the bulb [12].
Owing to the axonal growth-promoting properties and the
superior ability to interact with astrocytes, OECs transplantation
has emerged as a promising experimental therapy to treat axonal
injuries and been shown to induce anatomical and functional
repair of lesions of spinal cord [13,14,15]. After SCI, the
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ability of nerve fibres to regeneration but also on the provision of a
pathway along which they can elongate to reach appropriate
destinations. Transplanted OECs have been shown to migrate
with regenerating axons through an unfavorable CNS environ-
ment [16,17,18,19] and to mingle well with astrocytes in adult
brain [20,21]. Interaction with astrocytes at the lesion site results
in the formation of an OEC channel between the host astrocytic
pathways on either side of the lesion, being devoid of inhibitory
molecules and providing a pathway for the severed axons to
regenerate successfully across the lesion and reach tissue targets
[15]. However, the mechanism underlying OECs migration into
the lesion region remains elusive.
Here, we provided the first evidence that reactive astrocytes
attract OECs migration by secreted TNF-a not only in vitro but
also in damaged spinal cord, suggesting a mechanism for guiding
OECs migration into glial scar, which is crucial for OECs-
mediated axons regrowth beyond the lesion site.
Materials and Methods
Ethical Statements
All animals in this study were handled in strict accordance with
the recommended NIH guidelines for care and use of animals for
scientific purposes and were approved by the Animal Experimen-
tation Ethics Committee of Second Military Medical University.
Primary cell cultures
Primary OECs were prepared from olfactory bulb of adult wild-
type or GFP-transgenic Sprague-Dawley rats and purified by
differential cell adhesiveness [22]. Briefly, OECs were extracted
from olfactory nerve layer by trypsin treatment and plated on
uncoated 25-cm
2 culture flask two times, each for 36 h at 37uCi n
5% CO2. The non-adhesive cell suspension was collected and
then seeded onto disks pre-coated with poly-L-lysine (PLL,
0.1 mg/ml), and incubated with serum-containing DMEM/F-12
supplemented with 2 mM forskolin (Sigma) and 10 ng/mL bFGF
(Sigma). OECs purity was assessed by staining with S100. The
percentage of S100-positive cells in our culture system is more
than 95%.
Highly enriched primary astrocyte cultures were prepared from
the cerebral cortex of 2-day-old neonatal rat as described
previously [23] with slight modifications. After removal of the
meninges, the cerebral cortex was dissociated into a single-cell
suspension by trypsinization and mechanical disruption. The cells
were seeded on poly-L-lysine (PLL, 0.1 mg/ml, Sigma) coated
culture flasks and incubated in DMEM/F-12 containing 10%
foetal calf serum. The culture medium was replaced at 24 hours
and every 3 days thereafter. After 8–10 days, the cultures became
confluent and loosely attached microglia and oligodendrocyte
precursor cells were removed from the cell monolayer by shaking
the flasks on a rotary shaker at 260 rpm for 18–20 hours at 37uC.
Astrocytes were subsequently detached using trypsin-EDTA and
plated into PLL-coated 12-well plates or onto PLL-coated
coverslips. The percentage of GFAP-positive cells in our culture
system is more than 98%. Primary astrocyte cultures were
stimulated chemically with lipopolysaccharide (LPS, 10 mg/mL)
to induce astrocyte activation.
Spinal cord injury model
Adult male Sprague-Dawley (170–200 g) rats were used for
spinal cord injury study. Animals were maintained in a
conventional animal facility that was kept at a 12:12 h light–dark
cycle with water and food provided ad libitum.
Surgical procedures were performed as previous protocol [24]
with a slight modification. Animals were anaesthetized with 2%
pentobarbital sodium. Laminectomy was performed to expose the
dorsal surface of the T7-9 segment, followed by a spinal right
hemisection at T8 using a fine corneal blade (cut twice in the same
place to ensure complete section). Then, the dorsal back muscle
and skin were sutured in layers. Postoperatively, animals were kept
at 22–25uC on highly absorbent bedding, injected with cefazolin
sodium (40 mg/day) for up to 1 week, and received manual
bladder expression twice daily until reflexive bladder control
returned.
Preparation of culture conditioned medium
Astrocytes and reactive astrocyte-conditioned serum-free medi-
um was obtained by growing confluent astrocytes and LPS-treated
astrocytes for 48 hr in condition-defined medium that consisted of
DMEM/F-12 supplemented with 1% N2 (vol/vol), 10.1 ng/ml
T3, 400 ng/ml T4, 0.035% bovine serum albumin (BSA) and
20 mM leupeptin, respectively. The culture-conditioned serum-
free medium prepared in this way was filtered (0.22 mm filter) and
used for Boyden chamber migration assay.
Boyden chamber migration assay
To measure the motility of a group of OECs, Boyden chamber
migration assay was performed according to a previously described
protocol [22]. In brief, the polyethylene terephthalate filter
membranes were coated with laminin. OECs were detached by
trypsin/EDTA and then seeded onto the upper chamber at a
density of 4610
5 cells in 250 ml of culture medium containing 1%
serum per well. The upper chambers were inserted into the tissue-
culture wells and 750 uL culture medium containing 1% serum,
defined medium (consisted of DMEM/F-12 supplement with 1%
N2 (vol/vol), 10.1 ng/mL T3, 400 ng/mL T4, 0.035% bovine
serum albumin (BSA) and 20 mM Leupeptin) or condition-defined
medium were added to lower chamber. After incubation for 8 h at
37uC, nonmigratory cells on the upper membrane surface were
removed with a cotton swab, and migratory cells migrating
through the membrane pores and invading to the underside
surface of the membrane were fixed with 4% paraformaldehyde
and stained with Coomassie Brilliant Blue. For quantitative
assessment, the number of stained, migrating cells was then
counted under microscopy at five fields per filter in three
independent experiments.
Immunocytochemistry and F-actin staining
For immunocytochemical analysis, OECs or astrocytes on
coverslips were washed with phosphate buffered saline (PBS) and
fixed with 4% paraformaldehyde (PFA) in PBS for 20 min,
followed by permeabilization with 0.3% Triton X-100 in 0.1 M
PBS for 10 minutes. After blocking the non-specific binding with
10% normal goat serum in 0.1 M PBS, cells were incubated with
primary antibodies against nestin (Chemicon), GFAP (Sigma), P75
(Chemicon), TNFR1 (Santa cruz), p-ERK (Santa cruz) or S100
(Boster) at 4uC overnight. Cells were then washed and incubated
with fluorescence-conjugated secondary antibodies (Jackson Im-
munoResearch Laboratories, Inc.) for 60 minutes at RT. For
visualization of F-actin, cells were incubated with 0.1 mg/ml
TRITC-phalloidin (Sigma) for 40 min at RT.
Western blot
Astrocytes were rinsed briefly with ice-cold PBS and lysed for
5 min in SDS gel sample buffer. The cell lysates were denatured
by boiling for 10 minutes and then centrifuged for 10 min at
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sulfate (SDS)-polyacrylamide gel and then transferred onto
nitrocellulose membranes. Membranes were then blocked with
10% non-fat milk in 16 TBST and incubated with primary
antibodies against TNFR1 (Santa cruz), TNF-a (R & D), pERK
(Santa cruz) or ERK (Santa cruz). To control for differences in
protein loading, membranes were also incubated with anti-
GAPDH antibody (Sigma). After incubating with horseradish
peroxidase (HRP)-conjugated secondary antibodies (Sigma),
immunoreactive bands were visualized by chemiluminescence
reagents (ECL, Amersham).
RT-PCR
For RT–PCR, total RNA was extracted from cultured OECs
using TRIZOL Reagent (Invitrogen Corporation, Carlsbad, CA),
followed by the treatment with DNase I (DNA-free, Ambion,
Austin, TX). Synthesis of cDNA was carried out with the
Superscript First-Strand Synthesis System for RT-PCR (Invitrogen
Corporation, Carlsbad, CA). The following primers were used for
RT-PCR: TNFR1 forward primer (59-GAACACCGTGTG-
TAACTGCC-39) and reverse primer (59- ATTCCTTCACCCTC-
CACCTC-39); TNFR2 forward primer (59-GATGAGAAATCCC
AGGATGCAGTAGG-39) and reverse primer (59- TGCTACA-
GACGTTCACGATGCAGG-39); ß-actin forward primer (59-
AAGATTTGGCACCACACTTTCTAC-39) and reverse primer
(59-CACGGTTGGCCTTAGGGTT-39). Aliquots (2 ml out of
20 ml reaction) of each PCR reaction were taken at 35 cycles and
electrophoresed on a 1.0% agarose gel. Gels were stained with
ethidium bromide and photographed under ultraviolet light.
Immunohistochemistry
For immunohistochemical analysis, animals were deeply
anaesthetized with 2% pentobarbital sodium and perfused
transcardially with 4% PFA in 0.1 M PBS, pH 7.4. The spinal
cords were subsequently dissected from each animal and post-fixed
in the perfusing solution overnight at 4uC. Then, the tissues were
cryoprotected in 20% sucrose in PBS for 24–48 h at 4uC. Cryostat
sections (10 mm) were cut and mounted onto gelatin-subbed slides
and stored at 270uC. For immunostaining, the slides were
permeabilized and blocked with 0.3% Triton X-100/10% normal
goat serum in 0.1 M PBS for 15 min. Primary antibodies against
GFAP (Sigma), nestin (Chemicon) or TNF-a (R & D) were then
applied to the sections overnight at 4uC. The following day,
sections were incubated with fluorescence-conjugated secondary
antibodies (Jackson ImmunoResearch Laboratories, Inc.) and
examined by Olympus fluorescence microscopy.
In vivo migration assay
To investigate whether reactive astrocyte-derived TNF-a
affected the migration of implanted OECs, an in vivo migration
assay was performed as previously described [18]. Cultured GFP-
expressing OECs were harvested with 0.25% trypsin/1% EDTA
when they reached 80–90% confluence. Cell suspensions were
prepared at a concentration of 100,000 OECs/mL in DMEM and
maintained on ice for transplantation. Immediately after complet-
ing the SCI model of rats, 0.5 ml of OECs were stereotaxically
microinjected into the spinal cord dorsal column midline, 1.5 mm
rostral to the lesion site using a pulled glass micropipette with an
inner diameter of 40 mm. There were three transplantation
groups: In group 1, untreated OECs were injected into spinal
cord and received normal saline (N.S., 10 ml/day) through a pipe
embedded in subarachnoid space (N.S. group). In groups 2, OECs
pretreated with anti-TNFR1 antibody (1:100) for 30 min were
injected into spinal cord and received the antibody against
TNFR1 (10 ml/day) instead of N.S. (TNFR1 group). In group 3,
OECs pretreated with an irrelevant goat IgG (1:100) for 30 min
were injected into spinal cord and received the IgG (10 ml/day)
through the pipe (IgG group).
Ten days after treatment, animals were killed and a 1 cm length
of the spinal cord centered at the injury site was separated. For
quantification of the migration of implanted OECs, longitudinal
sections (10 mm) were cut in the horizontal plane. Every seven
section was collected and the grafted GFP-expressing OECs were
identified using a fluorescence microscope (IX70, OLYMPUS).
Cell location was measured as the straight-line distance from the
center of the injection site to the farthest OEC in the rostral and
caudal directions. The maximum measured distance that the cells
were located from the center of the lesion site of each animal was
averaged within each group.
Statistical analyses
All data presented represent results from at least three
independent experiments. Statistical analysis was performed using
Student’s t-test or the Kolmogorov-Smirnov test. Statistical
significance was defined as P,0.05.
Results
Glial scar tissue and reactive astrocytes promote OECs
migration
To determine effects of glial scar on OECs migration, we
measured the mobility of OECs by using a cell culture model of
migration of OECs with co-cultured glial scar tissue in a Boyden
chamber. The motility of OECs was determined by counting cells
migrated through the filter which were stained with Commassie
Blue. As shown in Fig. 1, co-culture with glial scar tissue but not
control tissue promotes the migration of OECs. As the glial scar is
composed primarily of reactive astrocytes induced by injury [2],
we next examined whether the migration-promoting effect of glial
scar tissue was mediated by reactive astrocytes. As shown in
Fig. 2A and B, treatment of astrocytes with LPS resulted in
stellation, extension of processes, re-expression of nestin, thick-
ening of F-actin and more prominent expression of GFAP, typical
of activated astrocytes. The reactive astrocyte-conditioned
medium but not astrocyte-conditioned medium increased the
motility of OECs in a concentration-dependent manner (Fig. 2C
and D).
Reactive astrocyte-derived TNF-a is responsible for the
promoting effect on OECs migration
When astrocytes were activated, they secreted a mass of
inflammatory factors, such as TNF-a, IL-1b, IL-6, c-IFN et al
[25,26,27,28,29]. Since TNF-a was shown to influence the
migration of various kinds of cells [30,31,32,33], we next tested
whether TNF-a released by reactive astrocytes was involved in
mediating the migration-promoting activity of OECs. We first
determined whether the receptors of TNF-a were expressed in
OECs. Fig. 3A showed that expression of TNFR1 but not TNFR2
mRNA transcripts was detected in cultured OECs by RT-PCR
analysis. The expression of TNFR1 in OECs was further confirmed
by immunostaining and western blotting analysis (Fig. 3B, C). In
addition, TNF-a was shown to exist in the condition medium of
reactive astrocytes induced by LPS (Fig. 4A). Boyden chamber
migration assay indicated that OECs migration was significantly
promoted by recombinant TNF-a protein in a dose-dependent
manner (Fig. 4B). When TNF-a antibody was added into the
culture medium, recombinant TNF-a-induced enhancement of
OECs migration was greatly attenuated (Fig. 4C). Antibody
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activity of recombinant TNF-a (Fig. 4D). Similarly, the ability of
reactive astrocyte-conditioned medium to enhance the motility of
OECs was significantly depressed by pretreatment of OECs with
anti-TNFR1 or blocking TNF-a in medium with antibody (Fig. 4E,
F). The motility of OECs was not influenced by treatment with
blocking antibodies (anti-TNF-a or anti-TNFR1) alone or an
irrelevant IgG, compared with the control (Fig. 4C–F). Together,
these results strongly suggested that the enhancement of OECs
migration was mediated by reactive astrocyte-derived TNF-a.
TNF-a induced migration of OECs is MAPK-dependent
Activation of the mitogen-activated protein kinase (MAPK) is
known to be an important step in the migration of vascular smooth
muscle cells [34,35]. In addition, TNF-a has been shown to induce
MAPK activation in several other cell types including fibroblasts
[36,37]. We therefore examined whether the MAPK pathway was
involved in TNF-a–induced OECs migration. As shown in Fig. 5A
and B, stimulation of OECs with reactive astrocyte-conditioned
medium or recombinant TNF-a protein resulted in prominent
activation of extracellular signal-regulated kinase 1/2 (ERK1/2).
OECs grown in astrocyte-conditioned medium or serum-free
medium demonstrated only weak ERK1/2 phosphorylation
(Fig. 5A, B). Treatment of OECs with reactive astrocyte-
conditioned medium or recombinant TNF-a induced a significant
increase in the amount of phosphorylated ERK1/2, which was
greatly attenuated by pretreatment of cells with PD98059, a
selective MAPK inhibitor (Fig. 5B, C). In the migration assay, the
promoting-effect of reactive astrocyte-conditioned medium on
OECs migration was significantly blocked after pretreating these
cells with PD98059 (Fig. 5D). Similarly, PD98059 also inhibited
the response of OECs toward TNF-a (Fig. 5E). In addition,
PD98059 alone did not change the migration activity of OECs
compared with the controls (Fig. 5D, E). Together, these results
suggested ERK signaling pathway was involved in mediating the
effect of TNF-a on OECs migration.
TNF-a secreted by reactive astrocytes in glial scar attracts
OECs migration
To investigate the effect of reactive astrocytes in glial scar on
OECs migration, we first detected the expression of TNF-a by
reactive astrocytes in glial scar using a spinal cord hemisection
model. Ten days after SCI, astrocytes surrounding the lesion
epicenter underwent a typical change of hypertrophy, process
extension and increased expression of intermediate filaments such
as GFAP and nestin, characteristic of reactive astrocytes (Fig. 6A).
By contrast, weak immunostaining for GFAP and nestin was
observed in distant areas, without obvious changes in cellular
morphology (Fig. 6A). Although TNF-a, a secretory protein, was
not colocalized well with GFAP, Fig. 6B showed that spinal cord
hemisection resulted in the expression of TNF-a and formed a
linear concentration gradient with the highest fluorescent density
in the region adjacent to the injury site (Fig. 6B). These data
implied that TNF-a was released from activated astrocytes
induced by CNS damage and the linear concentration gradient
of TNF-a might be a chemoattractive cue for OECs migration
toward the lesion site.
Using the co-culture model of cells migration described above,
we next examined the effect of glial scar prepared from injured
spinal cord on OECs migration 0, 1, 4, 7, 10 and 14 days after
SCI. As shown in Fig. 7A, the OECs migration-promoting effect of
glial scar tissue was time-dependent. Promoting the mobility of
OECs by glial scar tissue was observed as early as 1 day after SCI
and reached a maximum at 7 days after SCI, but it subsequently
decreased. When TNF-a secreted by reactive astrocytes in glial
scar was neutralized by anti- TNF-a antibody or TNR1 expressed
on OECs was blocked with anti-TNFR1, OECs migration
induced by glial scar tissue was greatly attenuated (Fig. 7B, C).
Figure 1. Analysis of the effect of glial scar tissue on OECs migration by a Boyden chamber migration assay. (A) Schematic
representation of the control tissue and glial scar tissue prepared from injured spinal cord. Seven days after SCI, the spinal cord spanning lesion site
was dissected and placed in Hank’s balanced salt solution. Glial scar tissue was prepared by cutting an approximately 1-mm-thick cross-section of
spinal cord in the region of glial scar. Control tissue was prepared by cutting an approximately 1-mm-thick cross-section of spinal cord distal to the
region of glial scar. The mobility of OECs was analyzed in a Boyden chamber migration assay. OECs were seeded onto the upper chamber at a density
of 4610
5 cells, with the spinal cord explants (control tissue or glial scar) plated into the lower chamber, and incubated 8 hr at 37uC. (B)
Photomicrograph of OECs transmigrated through the filter in the absence or presence of glial scar tissue. (C) Quantitative assessment of migrating
cells under different conditions. **P,0.01 versus control tissue group.
doi:10.1371/journal.pone.0008141.g001
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OECs were double-stained with antibodies against P75 and TNFR1 after treatment with Triton X-100. Scale bar=50 mm. (C) Western blotting analysis
for the expression of TNFR1 cell lysates of cultured OECs. GAPDH blotting severed as the loading control.
doi:10.1371/journal.pone.0008141.g003
Figure 2. Reactive astrocytes-conditioned medium promotes OECs migration. (A, B) lipopolysaccharide (LPS) stimulates astrocytes to
change into reactive astrocytes. After incubation with LPS (10 mg/mL) for 24 hr, astrocytes are activated to express nestin (A) and undergo an
extensive hypertrophy of their cell bodies and cytoplasmic processes and a massive up-regulation of GFAP (B). Scale bars: 50 mm (A); 25 mm (B). (C)
Reactive astrocyte-conditioned medium (RAC-CM) promotes OECs migration. After stimulation with defined medium (DM), astrocyte-conditioned
medium (AC-CM) or RAC-CM for 8 hr, the migrating cells in the Boyden chambers are stained with Coomassie Brilliant Blue and counted. **P,0.01
versus DM. (D) Enhancement of migration of OECs by RAC-CM is dose-dependent. *P,0.05 versus AC-CM, **P,0.01 versus AC-CM.
doi:10.1371/journal.pone.0008141.g002
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significantly decreased the migrated cells induced by glial scar
tissue (Fig. 7D). These results suggested that the effect of glial scar
tissue on the motility of OECs was mediated by secreted TNF-a.
We further determined whether TNF-a could attract implanted
OECs migration toward the lesion site in vivo. Immunocytochem-
istry revealed that 96.860.5% of GFP-expressing OECs were
labeled for the OECs marker S100 before grafting (Fig. 8A). After
transplantation 1.5 mm rostral to the spinal cord injury site, the
GFP labelled cells were predominantly elongate and bipolar,
suggestive of cell migration, near the edge of the area of injected
cells (Fig. 8B). As shown in Fig. 8C, grafted OECs migrated away
from the injection site. In uninjured spinal cord, there was no
significant difference in the migration distance between rostral and
caudual direction (Fig. 8C–E). Although OECs migration distance
was reduced in hemisected spinal cord, compared with the non-
injured spinal cord, there was a tendency of cells to move farther
in the caudal direction (toward the lesion site) than in the rostral
direction (Fig. 8C–E). However, treatment of OECs with anti-
TNFR1, but not normal saline or an irrelevant IgG, inhibited the
preferential caudal migration (Fig. 8C–E). Taken together, these
data suggested that TNF-a released from activated astrocytes
induced by SCI attracted OECs migrating toward lesion site in
vivo.
Discussion
Owing to the lack of axonal regeneration and reconnection with
correct synaptic targets, the repair of CNS damage, especially SCI,
continues to be a major challenge. Because of the existence of glial
Figure 4. Reactive astrocytes secrete TNF-a to promote OECs migration by interacting with TNFR1. (A) Reactive astrocytes produce
TNF-a. The cell lysate and condition medium of OECs treated (+) or untreated (2) with LPS (10 mg/mL) at 37uC for 24 hr were subjected to
immunoblotting with antibody against TNF-a (upper panel) and anti-GAPDH (lower panel). (B) Dose dependency of TNF-a effect on OECs migration.
*P,0.05 versus control, **P,0.01 versus control. (C, D) The effect of TNF-a on the migration of OECs is mediated by TNFR1. Medium or OECs were
pretreated with TNF-a antibody (5 mg/mL), TNFR1 antibody (2 mg/mL) or goat IgG for 2 hr and applied to Boyden chamber migration assays,
stimulated with TNF-a (50 ng/mL). Cells without pretreatment but with TNF-a stimulation were defined as TNF-a group. Cells with neither
pretreatment nor TNF-a stimulation were defined as control. **P,0.01 versus TNF-a group. (E, F) TNF-a in RAC-CM is involved in mediating the
migration-promoting activity of OECs. RAC-CM or OECs were pretreated with TNF-a antibody (5 mg/mL), TNFR1 antibody (2 mg/mL) or goat IgG for
2 hr, then stimulated with RAC-CM. Cells without pretreatment but with RAC-CM stimulation were defined as RAC-CM group. Cells without
pretreatment but with AC-CM stimulation were defined as AC-CM group. **P,0.01 versus RAC-CM group.
doi:10.1371/journal.pone.0008141.g004
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pass the lesion site. It has been reported that long-distance axonal
regeneration beyond the lesion centre in the transected adult
spinal cord is induced by transplantation of OECs [20,38,39].
OECs transplantation can inhibit hypertrophic response of host
astrocyte, reduce CSPG expression in reactive astrocytes, and
negatively regulate glial scar formation [21,40,41,42]. Several
studies report that OECs induce an increase in the formation of
new blood vessels after SCI [20,43,44,45], which may function as
a scaffold for migrating glia as well as for regrowing axons [44].
Data from Li et al. [46] demonstrate that OECs actively
phagocytose degenerating axons. Recent studies indicate that
OECs form a channel- or tube-like structure within the lesion to
provide an oriented matrix for axons to grow on or through
[15,17]. It is noteworthy that the migratory properties of OECs
are considered to account in part for their ‘‘repair’’ qualities, as
OECs are found to migrate and associate with extending axons
and are proposed to provide permissive conditions for axon
bridging beyond the injury site [20,38,47,39]. Importantly, grafted
OECs are shown to migrate preferentially toward the lesion site in
the damaged CNS [18]. In the present study, data from in vitro
assays showed that both LPS-induced reactive astrocytes and glial
scar tissue promote the migration of cultured OECs. Furthermore,
in the spinal cord contralateral hemisection model, OECs injected
rostral to lesion site were shown eventually to migrate from the site
of grafting centripetally toward the glial scar and into lesion
epicenter.
It has been proposed that OECs might respond to signals from
the damage epicenter, which account for their migrating
preferentially toward the injury site [38,48]. Astrocytes have the
capacity to secrete or respond to a variety of cytokines including
IL-1, IL-6, IL-3, and TNF-a. Evidences show that TNF-a,a n
important inflammatory factor, regulates the migration of various
kinds of cells. TNF-a and TNFR1 are required for migration of
follicular dendritic cell precursors into splenic follicles [30]. Studies
of Dekaris et al. [31] demonstrated that TNF-a regulates corneal
Langerhans cell migration. Additionally, TNF-a has also been
reported to induce the motility of intestinal epithelial cell and
Figure 5. ERK activation is critical for mediating the effect of TNF-a on OECs migration. (A, B) ERK activation in OECs was assessed with
immunocytochemistry (A) and western blot (B) after incubation with RAC-CM or recombinant TNF-a. Densitometric analysis is shown in the bottom
panel of (B) with the amount of p-ERK normalized to the amount of ERK. *P,0.05. Scale bar=50 mm. (C) PD98059 treatment significantly inhibited
the activation of ERK in OECs stimulated with RAC-CM or recombinant TNF-a. OECs were incubated with ERK-inhibitor PD98059 (30 mM) for 30
minutes before RAC-CM or TNF-a (50 ng/mL) was added. Densitometric analysis is shown in the bottom panel. *P,0.05. (D, E) In Boyden chamber
migration assay, the migration induced by RAC-CM or recombinant TNF-a was evidently attenuated when OECs were pretreated with PD98059.
**P,0.01 versus TNF-a or RAC-CM.
doi:10.1371/journal.pone.0008141.g005
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olfactory system, OECs has been shown to share some
characteristics of inflammatory cell [49,50,51,52,53]. For example,
data from recent microarray analysis of the transcriptome of
OECs document that the cell, compared to astrocytes and
Schwann cells, express higher levels of a number of innate
immune factors, which suggest that OECs may play a role in
modulating neuroinflammation [54]. OECs are also demonstrated
to possess the cellular machinery that permits them to respond to
certain bacterial ligands, and to mount a response through the
activation of nuclear factor kB (NFkB), an inflammatory
transcription factor, and cytokine production [52]. In this study,
Figure 6. Astrocytes are activated to secrete TNF-a in hemisection SCI model. (A)Ten days after SCI, immunohistochemical analysis was
performed for the reactive astrocytes with anti-GFAP and anti-nestin. (d, e) Higher magnification of the outlined areas in b and c showed reactive
astrocyte with an extensive hypertrophy of their cell bodies and cytoplasmic processes. (f) A merged picture of d and e. Scale bars: 500 mm (a–c);
50 mm (d–f). (B) TNF-a produced by reactive astrocytes was examined by double-stained with antibodies against nestin and TNF-a 10 days after SCI
(a–d). (e, f) Higher magnification of the outlined areas in b. Scale bars: 500 mm (a–d); 50 mm (e, f). Asterisk indicates the lesion site. Dashed line in B
indicates approximate border of the glial scar. Arrows indicate representative reactive astrocytes.
doi:10.1371/journal.pone.0008141.g006
Figure 7. The effect of glial scar on OECs migration is mediated by secreted TNF-a. (A) Glial scar promotes OECs migration in a manner of
time-dependence. *P,0.05 or **P,0.01 versus control tissue. (B, C) The effect of glial scar on OECs migration is mediated by TNF-a and TNFR1. OECs
were pretreated with TNF-a antibody (5 mg/mL), TNFR1 antibody (2 mg/mL) or goat IgG for 2 hours, and then incubated with glial scar tissue in a
Boyden chamber. Cells without pretreatment but with glial scar tissue stimulation were defined as glial scar tissue group. Cells without pretreatment
but with control tissue stimulation were defined as control tissue group. **P,0.01 versus glial scar tissue. (D) ERK activation is involved in glial scar-
induced OECs migration. PD98059 treatment significantly attenuated the effect of glial scar tissue on OECs migration. **P,0.01 versus glial scar tissue
group.
doi:10.1371/journal.pone.0008141.g007
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astroyctes induced by LPS. In the injured spinal cord, expression
of TNF-a by reactive astroyctes in glial scar was up-regulated and
formed a linear concentration gradient. Moreover, Boyden
chamber migration assay indicated that TNF-a was a chemoat-
tractant for OECs migration, and TNF-a blocking with antibody
greatly decreased the OECs migration activity. In addition,
TNFR1 (type 1 TNF-a receptor) but not TNFR2 (type 2 TNF-a
receptor) was shown to express in OECs, and we further
confirmed that the chemoattractive activity on the migration of
OECs was TNFR1-dependent by using anti-TNFR blockage. To
our knowledge, this is the first evidence that functional TNFR1 is
expressed on OECs. All these results supported the hypothesis that
in the injured spinal cord, reactive astrocytes in glial scar release
TNF-a to attract grafted OECs migrating from injection site into
lesion centre.
TNF-a has been shown to activate a number of signaling
pathways in various cell types [55,56,57] and these signaling
Figure 8. TNF-a attracts implanted OECs migration toward lesion site in vivo. (A) S100 immunolabeling of GFP-expressing OECs in vitro. The
majority of OECs cultured from GFP-transgenic rats express S100. (B) Higher power showing OECs at the edge of the injection site. Elongated profiles
(arrows), suggestive of cell migration, as well as round and multipolar GFP labelled cells can be seen. (C) Horizontal sections from intact and
contralateral hemisectioned spinal cords with GFP-expressing OECs injections 1.5 mm rostral to the lesion epicenter at the time of injury. The animals
with SCI were treated with normal saline (N.S.), anti-TNFR1 antibody or irrelevant goat IgG every day through a pipe embedded in the subarachnoid
space. Arrows indicate the injection site (IS) and lesion site (LS). (D) Quantitative assessment of cell migration at 10 days after transplantation into the
spinal cord. Mean and standard deviation of the migration distances in rostral and caudal directions are presented for each group. The white dot
indicates the migration distance for each injection. Blue bars, OECs into intact spinal cord; red bars, OECs into injured spinal cord and treated with
normal saline; green bars, OECs into injured spinal cord and treated with anti-TNFR1; black bars, OECs into injured spinal cord and treated with
irrelevant IgG. (E) Histogram showing the average migration ratio of the caudal to rostral direction. **P,0.01 versus normal saline or irrelevant IgG
group. Scale bars: 50 mm (A), 100 mm (B), 500 mm (C).
doi:10.1371/journal.pone.0008141.g008
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that the MAPK pathway is activated by TNF-a in fibroblasts [37]
and inflammatory cells [36]. TNF-a is shown to increase granulosa
cells proliferation by activating stress-activated protein kinase/c-
Jun-NH2-teminal kinase signaling [58]. In addition, evidences
from Sippy et al. indicate that induction of intercellular adhesion
molecule-1 by TNF-a is dependent on protein kinase C in human
retinal pigment epithelial cells [55]. In present study, we found
that the amount of active ERK1/2 was significantly increased in
OECs treated with reactive astrocyte-conditioned medium or
recombinant TNF-a, which suggested that TNF-a binding to
TNFR1 led to activation of ERK1/2 in OECs. PD98059
selectively inhibits the dual-specificity kinase MEK, which
phosphorylates and activates MAPK. Pretreating OECs with this
pharmacological inhibitor blocked the activation of ERK1/2 and
greatly attenuated the migration of these cells induced by reactive
astrocyte-conditioned medium, glial scar tissue, or recombinant
TNF-a. All these findings suggested that activation of ERK1/2
MAPK was a crucial event in TNF-a–directed migration of
OECs.
There were controversial reports regarding migration of
transplanted OECs in the injured spinal cord. Some studies show
that OECs readily coexist with reactive astrocytes and are able to
pass through this barrier when injected at the time of injury and
after a delay, following scar formation [15,17,21,40,59,60].
Reactive astrocytes, present in all type of injured cases do not
appear to limit the movement of OECs even if the glial scar had
already formed prior to OEC implantation. However, data from
other study demonstrate that the motility of grafted OECs in
damaged CNS is limited, with no OECs found migrating into glial
scar [19]. It is likely that the difference in the injection site and the
time for transplantation may account for the conflicting reports
about OECs migration in damaged spinal cord. As shown in the
present study, after SCI, a linear concentration gradient of TNF-a
is formed in the glial scar. If OECs are transplanted in a site far
away from lesion centre, the concentration of TNF-a may be too
low to attract OECs migrating into glial scar. Therefore,an
appropriate injection site is crucial for the grafted OECs to
response to signals or factors from glial scar. Previous studies
demonstrated that the functional improvement was achieved by
delayed transplantation of OECs [61,62,63]. Interestingly, our
data showed that the chemoattractive activity of glial scar tissue on
OECs migration is time-dependent, with a maximal activity at 7
days after SCI. This finding may be beneficial for guiding the
selection of time point for OECs transplantation after SCI.
In summary, our study provide the first evidence that TNF-a
released by reactive astrocytes attracts OECs migration. This work
suggests a molecular mechanism underlying OECs migration into
glial scar and indicates a novel function of reactive astrocytes in
OECs-based treatment for CNS injury.
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